Nurotron Biotechnology
Hangzhou Nurotron Biotechnology is a high-tech enterprise providing nerve electronic products
About Nurotron Biotechnology
Nurotron Biotechnology, established in 2006, operates within the medical device sector, specifically focusing on neuro-stimulation systems to address profound hearing loss. The company was co-founded by Li Chu and his father, Li Fangping. Li Fangping, a successful real estate developer, was inspired to enter the medical device field after learning about the significant number of people in China with hearing impairments and the high cost of foreign-made cochlear implants. His son, Li Chu, a graduate of Concordia University, brought his experience in international business to the venture. Their goal was to develop an affordable and effective cochlear implant system for the Chinese market and beyond.
The company's primary business involves the design, development, and manufacturing of these neuro-stimulation systems. Nurotron is headquartered in Hangzhou, China, with a research and development center located in Irvine, California. This strategic placement allows the company to leverage manufacturing capabilities in China while tapping into the R&D ecosystem in the United States. The company's business model is centered on selling its cochlear implant systems to hospitals and clinics that treat patients with severe to profound hearing loss. A significant portion of their market includes government tenders, such as a large order from the China Disabled Persons' Federation. By offering a more affordable alternative to established competitors, Nurotron has been able to significantly reduce the cost of cochlear implants in the Chinese market.
Nurotron's flagship product is the Venus Cochlear Implant System, designed for both children and adults. This system works to restore hearing for individuals who are totally deaf. A key feature of their implant is a 24-channel electrode array, designed to provide a high resolution of sound. The company has focused on creating a device that is not only effective but also easier for surgeons to insert, with a design aimed at minimizing surgical trauma. Over the years, Nurotron has developed newer models like the Enduro system, which is 30% smaller and offers more features than its predecessor. The company has received CE mark approval in Europe and regulatory clearance in several countries, including China, India, and Turkey, serving over 20,000 users worldwide. Beyond cochlear implants, Nurotron's patent portfolio includes developments in auditory brainstem implants and artificial vision systems.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 22.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Consumer Electronics, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Technology
- Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | May 2025 | — | — | Hangzhou Capital | ↗ |
| SERIES EEquity / VC | Oct 2020 | $24M | $96M | Undisclosed | — |
Growth signals
Latest recorded traffic for Nurotron Biotechnology is 2.2K monthly website visits, up 292.9% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Nurotron Biotechnology in the Hangzhou ecosystem
The Nurotron Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later2 investors entered at this stage
Kleiner Perkins
Hangzhou Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nurotron Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nurotron Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










